Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Fulgent FID-007 Phase 2 Results
Tech clinical trial results

Fulgent FID-007 Phase 2 Results

Analysis based on 8 articles · First reported May 21, 2026 · Last updated Jun 01, 2026

Sentiment
70
Attention
6
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive interim Phase 2 clinical trial results for FID-007 are expected to have a significant positive impact on Fulgent Genetics' stock price, as it validates their therapeutic development business. This success could attract further investment in the biotechnology and pharmaceutical sectors, particularly for companies developing novel cancer treatments.

Biotechnology Pharmaceuticals Healthcare
Event Summary

Fulgent Genetics announced and presented updated interim data from its open-label, randomized Phase 2 study of FID-007 in combination with Cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at the American Society of Clinical Oncology 2026 Annual Meeting. The abstract, entitled 'FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020', showed meaningful clinical activity and a favorable safety profile. Key observations included an objective response rate (ORR) of 60% and a median progression-free survival (mPFS) of 7.2 months. Raymond Yin and Guilherme Rabinowits highlighted the encouraging results, especially given the limited current standard of care for R/M HNSCC patients. A Phase 3 study is planned for FID-007.

Key Actions
95 FID-007 demonstrated anticancer activity
90 Fulgent Genetics presented updated data
90 FID-007 exhibited favorable safety
80 Fulgent Genetics announced abstract release
Entities Involved
stock
Fulgent Genetics
Fulgent Genetics announced positive interim results from its Phase 2 study of FID-007, which could significantly advance its therapeutic development business and potentially lead to a Phase 3 study. This positive data could increase investor confidence and its stock price.
Importance 100 Sentiment 75
oth
FID-007
FID-007 is the drug candidate developed by Fulgent Genetics that showed meaningful clinical activity and a favorable safety profile in combination with cetuximab for treating R/M HNSCC.
Importance 90 Sentiment 70
oth
Cetuximab
Cetuximab is a drug used in combination with FID-007 in the Phase 2 study, demonstrating synergistic effects in treating R/M HNSCC.
Importance 50 Sentiment 0
ngo
American Society of Clinical Oncology
The American Society of Clinical Oncology is hosting the annual meeting where Fulgent Genetics presented its FID-007 data, providing a platform for the dissemination of important clinical research.
Importance 40 Sentiment 0
per
Raymond Yin
Raymond Yin, Co-Founder and President of Fulgent Pharma, expressed encouragement regarding the clinical progress of FID-007 and its potential as a meaningful treatment.
Importance 30 Sentiment 0
per
Guilherme Rabinowits
Guilherme Rabinowits, a Principal Investigator, highlighted the encouraging clinical activity and manageable safety profile of FID-007 in combination with cetuximab.
Importance 30 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.